Stable Genes, Not Shuffling, Made a Superbug Dominant — Then It Fell

Then the stability broke. As the genome began to diversify, the clone declined in the hospital. The very features behind its success — antibiotic resistance genes, the ability to metabolize alternative sugars — were the ones it shed on the way down.

There was an inside job, too. Some descendants acquired the ability to produce bacteriocins, small antimicrobial molecules bacteria use to inhibit nearby competitors. In plain terms, the clone's own offspring developed chemical weapons against it. That extra edge, the researchers argue, helped finish off the ancestral line.

A genetic 'super-tool' for resistance

The team also identified a genetic element in the clone that behaved like a hybrid of a bacterial virus and a plasmid. This super-tool could carry and pass on multiple resistance genes as a single package.

"Using any one of those antibiotics can select for bacteria carrying the whole package, including vancomycin resistance," said Maria Miragaia, leader of the Bacterial Evolution and Molecular Epidemiology lab at ITQB NOVA and senior author of the study. "This means that simply reducing vancomycin use may not be enough to reduce vancomycin-resistant bacteria if other linked antibiotics are still being used."

That quote deserves a second read. It implies hospital antibiotic stewardship aimed at one drug may miss the target entirely when resistance genes travel bundled.

What does this change for infection control?

"Hospitals often only notice and respond to these clones once they have already spread widely," said Opeyemi Lawal, a former Ph.D. student at ITQB NOVA, now at Windsor University in Canada. "By understanding why this clone declined in the hospital, we can identify its weak points and use that knowledge to control similar multidrug-resistant bacteria in the future."

The study's practical pitch: target the persistence strategies themselves. If hospitals can disrupt biofilm formation, the bacterium's outer-surface modifications or its use of alternative sugars in the gut, they may clear these resistant bacteria from patients' digestive tracts and slow hospital spread.

A caveat, as always. This is one clone in one hospital over eight years. The findings challenge the plasticity assumption convincingly for this case, but nobody has shown the same stability-first pattern holds across other resistant lineages or other countries. The 2026 paper — Lawal et al., DOI: 10.1186/s13073-026-01747-2 — is a detailed autopsy, not yet a playbook.

Still, an autopsy of a superbug's decline is rarer than it sounds. Most research chases why these clones succeed. This one documents, gene by gene, how a winner lost.